National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vestronidase alfa (MEPSEVII®)

Vestronidase alfa is indicated for the treatment of non-neurological manifestations of MPS VII.


NCPE Assessment Process Complete
Rapid review commissioned 09/04/2017
Rapid review completed 22/05/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care.


The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.